Recent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.